Volltext verfügbar nach Anmeldung bzw. im Campus-Netz.
ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)
In: Business Wire (English), 2019-12-07
Online
Zeitungsartikel
Zugriff:
ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced new results from the hematological portion of the ALX148 Phase 1 program at the 2019 ASH Annual Meeting [publication number #1953]. As of November 01, 2019, twenty-nine patients with relapsed or refractory non-Hodgkin lymphoma (NHL) were administered ALX148 in combination with a standard rituximab regimen. Objective responses were observed at all dose levels administered. [ABSTRACT FROM PUBLISHER]
Titel: |
ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)
|
---|---|
Autor/in / Beteiligte Person: | Oncology, ALX |
Zeitschrift: | Business Wire (English), 2019-12-07 |
Veröffentlichung: | 2019 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|